Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LGVN | US
0.02
3.29%
Healthcare
Biotechnology
30/06/2024
08/06/2026
0.75
0.73
0.80
0.73
Longeveron Inc. a clinical stage biotechnology company develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young healthy adult donors. It is conducting Phase 1 Phase 2a and Phase 2b clinical trials in various indications such as aging-related frailty alzheimer's disease metabolic syndrome acute respiratory distress syndrome and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami Florida.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
64.9%1 month
85.5%3 months
164.5%6 months
128.5%-
-
2.13
0.12
0.09
-49.61
17.17
-
-17.22M
10.83M
10.83M
-
-747.86
-
115.70
-142.16
1.60
6.01
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.13
Range1M
0.25
Range3M
0.74
Rel. volume
0.26
Price X volume
80.60K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| GeoVax Labs Inc | GOVX | Biotechnology | 1.34 | 11.42M | -18.79% | n/a | -6.03% |
| Lipocine Inc | LPCN | Drug Manufacturers-Specialty & Generic | 2.04 | 10.91M | -0.49% | n/a | 0.00% |
| CALC | CALC | Biotechnology | 0.958 | 10.30M | -9.62% | n/a | 0.00% |
| Cocrystal Pharma Inc | COCP | Biotechnology | 1.01 | 10.28M | 4.74% | n/a | 10.24% |
| Lexaria Bioscience Corp | LEXX | Biotechnology | 0.6466 | 10.22M | 1.51% | n/a | 1.41% |
| VYNE Therapeutics Inc | VYNE | Biotechnology | 0.6586 | 9.71M | 0.38% | 1.29 | 0.19% |
| Hoth Therapeutics Inc | HOTH | Biotechnology | 1.36 | 9.39M | -9.93% | n/a | 0.44% |
| Anebulo Pharmaceuticals Inc. Common Stock | ANEB | Biotechnology | 0.3602 | 9.34M | -3.95% | n/a | 0.00% |
| KPRX | KPRX | Biotechnology | 2.58 | 7.66M | 3.20% | 0.21 | 0.25% |
| Cyclerion Therapeutics Inc | CYCN | Biotechnology | 3.01 | 7.57M | 1.01% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4131 | 7.98M | -3.48% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -49.61 | 0.53 | Cheaper |
| Ent. to Revenue | 17.17 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.13 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 164.50 | 72.80 | Riskier |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.09 | 0.25 | Cheaper |
| Market Cap | 10.83M | 3.66B | Emerging |